Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA(TM) (Cyclobenzaprine HCl Sublingual Table... GlobeNewswire
Market data is delayed by at least 15 minutes.
    Latest Story
    Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA(TM) (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit
     GlobeNewswire
    Full Story →

    Headline News
    Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026
    7:00a ET January 6 '26 GlobeNewswire
    Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering
    7:57a ET December 29 '25 GlobeNewswire
    Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800)
    7:45a ET December 29 '25 GlobeNewswire
    More News →
    Day  1.13%Week  0.99%Month  10.50%More Charting →
    Today, 11:33a ET Thursday February 19 '26. Markets Open.
    Last $15.25
    Day change   1.13%$0.17
    Open $15.01
    Gap at open $0.07
    Previous close $15.08
    Trading volume 89,903
    10 Day avg vol. 281,017
    Shares out. 12.8Mil
    Market cap. $195.1Mil
    Trading activity Above Avg.
    Previous data from yesterday, February 18 '26.

    Historical Price Performance
    3 month   5.28% 
    6 month   59.85% 
    1 year   52.50% 
    2 year   98.73% 

    Earnings
    Previous 12m -$20.11
    Next 12m Estimate -$13.43
    P/E ratio --
    Revenue 10Mil

    Market data provided by News provided by